kidney disease and semaglutide in patients with overweight or obesity chronic without diabetes: a randomized double-blind placebo-controlled clinical trial Semaglutide could be 'practice changing'

A detailed history should explore the timeline of ED onset relative to semaglutide initiation, severity and progression of symptoms, presence of morning erections, relationship factors, and psychological stressors

With reliable protection, you can focus on healthy choices rather than defensive dietary restriction, engage fully in supportive social situations, and persist with treatment long enough for meaningful results rather than abandoning it due to temporary embarrassment

Recalculating every four to six weeks is a sensible approach

Competing interests BV reports grants and institutional fundings from Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, LifeScan, Lilly, MSD, NovoNordisk, and Recordati

Cross-reference with the chart